Chandra Bhagat Pharma Ltd.
BBSE:CBPL40.00
INR
0.00
(0.00%)
ISIN
INE07QQ01016
Return %
Stock
S&P 500
1Y
-2.72
14.20
3Y
-62.88
81.12
5Y
-66.46
68.34
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Semi-annual Revenue
INR
•
in mil. unless spec.Semi-annual Earnings Per Share
INR
•
in mil. unless spec.Semi-annual Dividends Per Share
INR
•
in mil. unless spec.Company Description
- CEO
- Hemant Chandravadan Bhagat
- Full Time Employees
- 37
- Sector
- Distribution services
- Industry
- Medical distributors
- Address
- Bhagat Bhuvan Mumbai MA India 400019
- IPO Date
- Feb 14, 2020
- Website
- cbcpharma.com
- Similar Companies
- Business
- Chandra Bhagat Pharma Limited is an India-based pharmaceutical company engaged primarily in the manufacturing, marketing, and distribution of pharmaceutical formulations and active pharmaceutical ingredients (APIs). Established in 2003 and headquartered in Mumbai, Maharashtra, the company’s core product portfolio includes intravenous (IV) and intramuscular (IM) injections, tablets, and capsules across several therapeutic categories such as oncology (anti-cancer), antibiotics, anesthesia, hormones, orthopedics, cardiovascular, anti-fungal, antiviral, pediatrics, nephrology, and neurology. The company also imports, supplies, and indents specialty chemicals, intermediates, and APIs, serving hospitals, healthcare institutions, government agencies, NGOs, and distributors. It operates with a contract manufacturing model backed by FDA approvals for its formulations and maintains warehousing facilities primarily in Bhiwandi, Maharashtra. Recently, Chandra Bhagat Pharma Limited has reinforced its presence in both domestic and international markets, exporting pharmaceutical formulations to countries including DR Congo, Bolivia, and the Philippines. The company has reported audited financial results for FY25 with unmodified opinions, signaling operational stability. It has appointed Amit Dharmani & Associates as secretarial auditors for FY 2024-25 and has focused strategically on contract manufacturing and sourcing approved pharmaceutical formulations. Promoters have increased their holding to 72.19% as of September 2025, indicating a consolidation of control. There have been no major acquisitions or joint ventures disclosed in the past 1-2 years, but the company continues to expand its product offerings, particularly in injection-based critical care medicines such as ITV and IM injections. Chandra Bhagat Pharma serves a diversified customer base in India and internationally, leveraging long-standing relationships with multinational corporations and healthcare providers. It operates under its own sales force and distribution network, marketing products under various brand names such as Amikas (Amikacin), Blastoplatin (Carboplatin), Nitrovir (Glyceryl Trinitrate), Clopam (Pralidoxime), and many others. The company’s therapeutic repertoire includes critical treatment areas like cardiovascular diseases, oncology, antibiotics, hormone therapy, and more. Its business model emphasizes customer-centricity, contract manufacturing, and compliance with regulatory standards to maintain quality and efficacy. Overall, Chandra Bhagat Pharma Limited is positioned as a comprehensive pharmaceutical supplier with a robust product mix in injections, tablets, capsules, APIs, and specialty chemicals, targeting hospitals and healthcare institutions primarily in India and select international markets. The company continues to solidify its footprint in life-saving medicines and critical therapeutic categories while maintaining operational and financial discipline. This description reflects the company’s current business activities, products, geographic operations, and recent corporate developments as of late 2025.